# IGF::OT::IGF EFFECT OF ASPIRIN ON BIOMARKERS OF BARRETT'S ESOPHAGUS AFTER SUCCESSFUL ERADICATION OF BARRETT'S ESOPHAGUS WITH RADIOFREQUENCY ABLATION

> **NIH NIH N01** · UNIVERSITY OF TX MD ANDERSON CAN CTR · 2021 · $2,604

## Abstract

The overall objective of this task order shall be to perform a pilot clinical trial testing the effects of aspirin on biomarkers associated with risk of recurrence of BE and/or esophageal adenocarcinoma in post-ablation esophageal biopsies

## Key facts

- **NIH application ID:** 10479746
- **Project number:** 261201200034I-P00006-26100007-1
- **Recipient organization:** UNIVERSITY OF TX MD ANDERSON CAN CTR
- **Principal Investigator:** POWEL BROWN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,604
- **Award type:** —
- **Project period:** 2015-06-15 → 2021-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10479746

## Citation

> US National Institutes of Health, RePORTER application 10479746, IGF::OT::IGF EFFECT OF ASPIRIN ON BIOMARKERS OF BARRETT'S ESOPHAGUS AFTER SUCCESSFUL ERADICATION OF BARRETT'S ESOPHAGUS WITH RADIOFREQUENCY ABLATION (261201200034I-P00006-26100007-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10479746. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*